Mycophenolate Mofetil

A liver transplant, also known as a hepatic transplant, is a surgical procedure that is performed when a patient's liver is not capable of performing basic functions, such as synthesizing proteins, carbohydrates, and fats. After the kidney, the liver is the second most frequently transplanted major organ, indicating the seriousness of the liver disease. Despite the fact that the majority of liver transplant operations use livers from deceased donors, it is still possible to obtain a liver from a living person as well (allograft). Current liver transplant demand is substantial, however only critically ill patients are considered for transplants, and these patients are selected based on their critical condition. NEWARK, DE / ACCESSWIRE / December 3, 2024 / The Liver Transplantation Market 2023 to 2033 is witnessing significant growth, reflecting advancements in medical technology and rising prevalence of liver-related diseases. In 2023, the market is valued at USD 1,409.8 million and is projected to reach USD 2,653.4 million by 2033, marking a robust CAGR of 6.5% over the forecast period.The increasing incidence of liver disorders such as cirrhosis and hepatocellular carcinoma is a major driver. According to WHO, nearly 2 million deaths annually are attributed to liver diseases globally. This has spurred a demand for innovative transplantation techniques and improved donor-recipient matching systems.Government and private sector investments in healthcare infrastructure and organ transplantation programs are creating lucrative opportunities. Additionally, the emergence of minimally invasive techniques and the integration of AI-based tools in organ matching and post-operative care have revolutionized the liver transplantation landscape.As the market expands, Asia-Pacific and North America are expected to dominate due to increased healthcare spending and better awareness programs, while advancements in biotechnology continue to drive the innovation curve.What Factors are Driving Growth of the Liver Transplantation Market?As hepatitis A, B, and C incidence increases worldwide, the liver transplantation market is expected to grow in the coming years. A major driving force in the liver transplantation market is the advancement of treatment and the increase in adoption as the most effective method of managing end-stage liver disease.Additionally, reimbursement policies are likely to become increasingly favorable in the near future, leading to a growth in liver transplantation. The fact that organ transplantation is becoming an increasingly popular treatment for organ failure is one of the most significant factors contributing to the growth of the market.During the coming years, the market will experience a great deal of growth due to the rise of passive lifestyles, bad eating habits, excessive drinking, and drug abuse being among the main factors that are driving the market to grow. Various causes of liver failure among the global population as well as the growing geriatric population have increased the demand for liver transplants in various regionsRequest a Sample Copy of This Report Now: https://www.fmisamplereport.com/sample/rep-gb-1281Key Takeaways from Market StudyMarket Size in 2023: USD 1,409.8 millionMarket Size in 2033: USD 2,653.4 millionCAGR (2023-2033): 6.5%Key Growth Regions: North America, Asia-Pacific"The liver transplantation market is entering a dynamic growth phase with the integration of cutting-edge technologies such as AI and robotic surgeries. While the increasing burden of liver diseases presents challenges, the market's rapid adaptation to patient needs and regulatory frameworks ensures a promising future. Public-private collaborations will play a pivotal role in accelerating accessibility and affordability." Says Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.)Restricting Factors for the Global Liver Transplantation Market?There are several risks associated with this procedure, including severe bleeding and negative reactions that can be life-threatening, which is a restraint on its use. Several other diseases that can occur as a result of transplants, such as diabetes, high cholesterol, and diarrhea, may impact the market's growth. Staying in a hospital for a long period of time can be expensive, which can hamper the growth of the liver transplantation market.In addition, there are several factors that contributed to the sharp decline in the market's revenue not only in recent years, but also in the future, including the shortage of primary intensive care units, protective equipment, and blood products during transplantation. Over the forecast period, however, liver transplantation market growth can be hindered by a shortage of liver donors, increased waiting lists for liver transplants, and an increase in hospitalization time and costs. As a result, liver transplantation will see a decline in market share in the near future. Component InsightsThe liver transplantation market comprises key components such as immunosuppressive drugs, surgical equipment, and post-operative care services. Among these, immunosuppressive drugs hold the largest share due to their essential role in preventing graft rejection.Growth DriversAdvanced Surgical Techniques: Minimally invasive procedures reduce patient recovery times and risks.Rising Awareness: Growing public understanding of liver health and the importance of transplantation.Supportive Regulations: Policies facilitating faster approvals of new portable medical devices and drugs.Emerging Innovators Are Leading a Transformation in Liver TransplantationA new wave of innovative start-ups, particularly in Western markets, is reshaping the liver transplantation landscape. These companies are introducing cutting-edge medical devices aimed at streamlining transplant procedures, ultimately offering significant benefits to both donors and recipients.Several European firms are pioneering advancements in the preservation of livers donated by both living and deceased individuals. Traditionally, the usable window for a liver after removal from the body is just 12 hours, beyond which the organ is no longer viable for transplantation. Efforts are underway to extend this critical time frame, providing more flexibility and improving patient outcomes.HepaTx, a U.S.-based company, is making strides in the field of regenerative medicine. They are developing stem cell-based therapies as alternatives to liver transplants, targeting patients with late-stage liver diseases. According to their data, only one in thirty-three patients in need of a liver transplant receives an organ in time, highlighting the ongoing challenges in the donor-recipient imbalance despite significant government investments in healthcare.Recent Advancements in Liver TransplantationA ground breaking procedure took place in September 2023 at Jaslok Hospital and Research Center in Mumbai, where a single liver was used to save two lives through a split cadaver liver donation surgery. This method divides the liver into two parts, enabling both an adult and a pediatric patient to benefit from the transplant simultaneously.In another notable development, the Liver4Life team at the University of Zurich has created an innovative blood perfusion machine. This device has the potential to extend the preservation time of a liver to 72 hours, a significant improvement over the previous 12-15 hours. The normothermic perfusion machine mimics the function of a human body by pumping blood to the liver, while supplying essential nutrients and medications to keep the organ in optimal condition before transplantation. This breakthrough has the potential to dramatically improve the viability of donor livers, making a substantial impact on the field.In-Depth Market Analysis: A Complete Reporthttps://www.futuremarketinsights.com/reports/liver-transplantation-marketKey Market PlayersAllosourceConatus Pharmaceuticals Inc.Digna Biotech S.L.Dompe Farmaceutici S.p.A.Isogenis, Inc.RedHill Biopharma Ltd.Thompson SurgicalIntegra Life SciencesBaxter International Inc.XVIVOVirTech BioVital TherapiesHepaTxHumedicsRegional Analysis of Liver Transplantation MarketNorth America: Largest market share with advanced healthcare infrastructure.Europe: Strong government support and rising organ donation rates.Asia-Pacific: Fastest growth driven by increasing medical tourism and awareness.Middle East & Africa: Emerging market due to improved healthcare facilities.Key Segments Profiled in the Global Liver Transplantation MarketBy Treatment Type:Liver Transplantation SurgeryPost-Surgery Anti-Rejection TreatmentCyclosporineTacrolimusSirolimus Prednisone AzathioprineMycophenolate MofetilBy End Use:HospitalsAdult Liver Transplantation CentersAmbulatory Surgical CentersBy Region:North AmericaLatin AmericaEuropeAsia PacificThe Middle East and AfricaAuthorSabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.Explore FMI's Extensive Coverage in the Healthcare Domain:The global liver fibrosis treatment market is expected to surpass an impressive valuation of USD 16.43 billion in 2023 and is projected to exhibit a CAGR of 11% from 2023 to 2033.The injectable drug delivery market is, according to industry analysis, estimated to be around a staggering USD 49.44 billion, as of 2024.The global drug delivery technology market is expected to be valued at USD 43.9 billion in 2023.The global hematopoietic stem cell transplantation market garnered a market value of USD 7 Billion in 2023The cross-species organ transplantation market is projected to be valued at USD 14.8 billion by 2024 and rise to USD 30.5 billion by 2034.The global medical cannula market size is forecast to reach USD 445 Million in 2022.The global medical robot market growth is poised to garner a 12.9% CAGR through 2034.The United States digital ovulation test kits market size is projected to be valued at USD 77.4 million in 2023 and is expected to rise to USD 185.0 million by 2033.The Cardiac Biomarker Diagnostic Test Kits Market size is projected to be worth USD 1,950 million in 2023.The global digital psychotherapeutics market size is projected to be worth US$ 1.06 billion in 2023. Over the next ten years, global digital psychotherapeutics demand is likely to accelerate at 27.6% CAGR.Trending TopicGlobal Skin Substitutes Market Analysis (2024-2034)About Future Market Insights (FMI)Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai and has delivery centres in the United Kingdom, the United States, and India. FMI's latest market research reports and industry analysis helps businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.Join us as we commemorate 10 years of delivering trusted market insights. Reflecting on a decade of achievements, we continue to lead with integrity, innovation, and expertise.Contact UsFuture Market Insights Inc.Christiana Corporate, 200 Continental Drive,Suite 401, Newark, Delaware - 19713, USAT: +1-347-918-3531For Sales Enquiries: [email protected]Website: https://www.futuremarketinsights.comLinkedIn | Twitter | Blogs | YouTubeSOURCE: Future Market Insights, Inc.

New Guidelines Presented at ACR Convergence 2024 Recommend First-Line Therapy with LUPKYNIS® (voclosporin) as Part of a Triple Immunosuppressive LN Treatment Regimen ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) commends the American College of Rheumatology (ACR) for their 2024 evidence-based guidelines for the screening, treatment, and management of lupus nephritis (LN), which prioritize the urgent need to use efficacious treatments to avoid nephron loss and preserve kidney function. The guidelines call for a triple immunosuppression treatment regimen for LN, with first line use of advanced therapies like LUPKYNIS for three to five years. Importantly, the guidelines suggest that steroids should be rapidly tapered to <5 mg/day by six months as the highest acceptable maintenance dose of steroids. The guidelines also call for achieving a proteinuria target of <0.5g/g urine protein creatinine ratio (UPCR) by 12 months of treatment. The recommendations included within the guidelines for use of LUPKYNIS to treat LN were based on the AURORA Clinical Program, including the Phase 3 AURORA 1 clinical study. In AURORA 1, patients were 81% more likely to achieve a complete renal response1 at 52 weeks (40.8 vs 22.5 – OR 2.7) with LUPKYNIS in combination with mycophenolate mofetil (MMF) and low-dose glucocorticoids, compared to MMF and low-dose glucocorticoids alone. Additionally, > 80% of patients were tapered to a steroid dose of <2.5mg / day by 16 weeks per the AURORA protocol, making LUPKYNIS the only therapy to meet and exceed the new guideline steroid target of <5mg /day by 6 months in randomized clinical trials. LUPKYNIS, the only FDA-approved CNI therapy for the treatment of adult patients with active LN in combination with other immunosuppressive therapies​, has demonstrated broad clinical utility across biopsy class, baseline eGFR, proteinuria range, race, ethnicity, age, and gender. Please see Indication and Important Safey Information, including Boxed Warning, below. The guidelines recommend routine urine screening for proteinuria at least every six to 12 months in patients with SLE without known kidney disease, or when experiencing extra-renal flares. They also conditionally recommend performing a kidney biopsy in patients with SLE who have high levels of protein in the urine (> 0.5 g/g) and/or impaired kidney function not otherwise explained. “We applaud ACR’s critical and timely guidelines to improve the management of lupus nephritis for this underserved patient population. They provide clear guidance for the importance of early diagnosis and starting with triple immunosuppression therapy with CNIs like LUPKYNIS to help achieve a complete renal response and aid in preserving kidney function for adults living with lupus nephritis,” said Dr. Greg Keenan, Chief Medical Officer at Aurinia. The updated ACR guidelines for the diagnosis and treatment of LN are based on systematic evidence reviews, feedback from a panel of people living with LN, and input from rheumatologists and nephrologists. About LUPKYNIS LUPKYNIS is a novel, structurally modified calcineurin inhibitor (CNI) with a dual mechanism of action, acting as an immunosuppressant through inhibition of T-cell activation and cytokine production and promoting podocyte stability in the kidney. The AURORA Clinical Program, comprised of the AURORA 1 pivotal trial and AURORA 2 extension trial, demonstrated the importance of LUPKYNIS plus standard of care to preserve kidney health in patients with active LN without reliance on chronic high-dose glucocorticoids. It is the only clinical program to include three years of LN treatment and follow-up with mycophenolate mofetil (MMF) and steroids. About Aurinia Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a differentiated, potential best-in-class therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). INDICATION AND IMPORTANT SAFETY INFORMATION INDICATION LUPKYNIS is indicated in combination with a background immunosuppressive therapy regimen for the treatment of adult patients with active lupus nephritis (LN). Limitations of Use: Safety and efficacy of LUPKYNIS have not been established in combination with cyclophosphamide. Use of LUPKYNIS is not recommended in this situation. IMPORTANT SAFETY INFORMATION BOXED WARNINGS: MALIGNANCIES AND SERIOUS INFECTIONS Increased risk for developing malignancies and serious infections with LUPKYNIS or other immunosuppressants that may lead to hospitalization or death. CONTRAINDICATIONS: LUPKYNIS is contraindicated in patients taking strong CYP3A4 inhibitors because of the increased risk of acute and/or chronic nephrotoxicity, and in patients who have had a serious/severe hypersensitivity reaction to LUPKYNIS or its excipients. WARNINGS AND PRECAUTIONS Lymphoma and Other Malignancies: Immunosuppressants, including LUPKYNIS, increase the risk of developing lymphomas and other malignancies, particularly of the skin. The risk appears to be related to increasing doses and duration of immunosuppression rather than to the use of any specific agent. Serious Infections: Immunosuppressants, including LUPKYNIS, increase the risk of developing bacterial, viral, fungal, and protozoal infections, including opportunistic infections which lead to serious, including fatal outcomes. Nephrotoxicity: LUPKYNIS, like other calcineurin inhibitors (CNIs), may cause acute and/or chronic nephrotoxicity. The risk is increased when CNIs are concomitantly administered with drugs associated with nephrotoxicity. Monitor eGFR regularly. Hypertension: Hypertension is a common adverse reaction of LUPKYNIS therapy and may require antihypertensive therapy. Monitor blood pressure regularly. Neurotoxicity: LUPKYNIS, like other CNIs, may cause a spectrum of neurotoxicities: severe include posterior reversible encephalopathy syndrome (PRES), delirium, seizure, and coma; others include tremor, paresthesia, headache, and changes in mental status and/or motor and sensory functions. Monitor for neurologic symptoms. Hyperkalemia: Hyperkalemia, which may be serious and require treatment, has been reported with CNIs, including LUPKYNIS. Concomitant use of agents associated with hyperkalemia may increase the risk for hyperkalemia. Monitor serum potassium levels periodically. QTc Prolongation: LUPKYNIS prolongs the QTc interval in a dose-dependent manner when dosed higher than the recommended lupus nephritis therapeutic dose. The use of LUPKYNIS in combination with other drugs that are known to prolong QTc may result in clinically significant QT prolongation. Immunizations: Avoid the use of live attenuated vaccines during treatment with LUPKYNIS. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment with LUPKYNIS. Pure Red Cell Aplasia: Cases of pure red cell aplasia (PRCA) have been reported in patients treated with another CNI immunosuppressant. If PRCA is diagnosed, consider discontinuation of LUPKYNIS. Drug-Drug Interactions: Avoid co-administration of LUPKYNIS and strong CYP3A4 inhibitors or with strong or moderate CYP3A4 inducers. Co-administration of LUPKYNIS with strong CYP3A4 inhibitors is contraindicated. Reduce LUPKYNIS dosage when co-administered with moderate CYP3A4 inhibitors. Avoid use of LUPKYNIS with strong or moderate CYP3A4 inducers. ADVERSE REACTIONS The most common adverse reactions (≥3%) were glomerular filtration rate decreased, hypertension, diarrhea, headache, anemia, cough, urinary tract infection, abdominal pain upper, dyspepsia, alopecia, renal impairment, abdominal pain, mouth ulceration, fatigue, tremor, acute kidney injury, and decreased appetite. SPECIFIC POPULATIONS Pregnancy: Avoid use of LUPKYNIS. Lactation: Consider the mother’s clinical need for LUPKYNIS and any potential adverse effects to the breastfed infant when prescribing LUPKYNIS to a lactating woman. Renal Impairment: LUPKYNIS is not recommended in patients with baseline eGFR ≤45 mL/min/1.73 m 2 unless benefit exceeds risk. If used in this population, reduce LUPKYNIS dose. Hepatic Impairment: For mild or moderate hepatic impairment, reduce LUPKYNIS dose. Avoid use with severe hepatic impairment. Please see Prescribing Information, including Boxed Warning, and Medication Guide for LUPKYNIS. References ________________________ 1 In the AURORA clinical program, complete renal response is defined as UPCR of 0.5 mg/mg or less, along with other criteria: stable renal function, defined as an estimated glomerular filtration rate (eGFR) of at least 60 mL/min/1.73 m2, or no more than a 20% decrease from baseline in eGFR; no rescue medication; no more than 10 mg prednisone equivalent per day for at least 3 consecutive days, or 7 or more days between weeks 44 and 52. View source version on businesswire.com: https://www.businesswire.com/news/home/20241118903839/en/ Media & Investor Inquiries: Andrea Christopher Corporate Communications & Investor Relations Aurinia Pharmaceuticals Inc. achristopher@auriniapharma.com General Investor Inquiries: ir@auriniapharma.com Source: Aurinia Pharmaceuticals Inc. Released November 18, 2024